Therapeutic Management of CLL

Therapeutic Management of CLL

Episodes

Specialty:

All

Year:

All

EP. 1: Risk Stratification in CLL

August 23rd 2017

EP. 2: CLL: Factors for Upfront Therapy

August 23rd 2017

EP. 3: Patient Selection for CLL Treatment

August 23rd 2017

EP. 4: Treatment for Cytogenetic-related Outcomes in CLL

August 23rd 2017

EP. 5: CLL: The Biologics of Ibrutinib Therapy

August 23rd 2017

Trending on OncLive

Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC

Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC

Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC

Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer